Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
CALGARY, AB, Sept. 29, 2026 /PRNewswire/ -- Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine programs,...
Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial
Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. CALGARY, AB and BRISBANE, Australia , Feb. 5, 2026 /PRNewswire/ -- Providence Therapeutics, a Canadian...
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, marking an...